Develops novel therapeutics for chronic Hepatitis B virus (HBV) infection. Develops antiviral medicines to treat SARS-CoV-2 and other coronaviruses. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $14.1M a year. A small number, but proof the product has real buyers.
There is $91.5M in the vault; even if every debt were paid off, $87.3M would remain.
Over the last 12 months, company executives reported 20 buys and 4 sells. Management buying with its own money is usually read as a good sign.
A loss of $33.5M against $14.1M in annual sales.
Right now the product sells for less than it costs to make; every sale deepens the loss.
Costs swallow the gains that sales growth brings in.
On our five-subject report card, ABUS sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ABUS is a high-risk stock — not yet profitable, and its future rides on its product catching on.